The Korea Times on MSN19h
Celltrion envisions 13 new drugs; Samsung Bio unveils 6th plant plan
Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...
manilatimes2h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
GlobalData on MSN7h
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead
CFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January. The company maintains a confident outlook for the new year, said Sarin, ...
Hosted on MSN15m
Samsung Biologics, Celltrion announce major expansion into ADC production
South Korea’s two leading biopharmaceutical companies, Samsung Biologics and Celltrion, unveiled ambitious plans to enter the ...
clinicaltrialsarena7h
Zai Labs announces positive results in China arm of Phase III cervical cancer trial
Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s regulatory plans.
Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
News Medical on MSN21h
A new strategy for enhancing the production of protein-based drugs
An international team of researchers led by the University of California San Diego has developed a new strategy to enhance ...